Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor

AIMS: Navoximod (GDC‐0919, NLG‐919) is a small molecule inhibitor of indoleamine‐2,3‐dioxygenase 1 (IDO1), developed to treat the acquired immune tolerance associated with cancer. The primary objectives of this study were to assess navoximod's absolute bioavailability (aBA), determine the mass...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Shuguang, Suchomel, Julia, Yanez, Evelyn, Yost, Edward, Liang, Xiaorong, Zhu, Rui, Le, Hoa, Siebers, Nicholas, Joas, Lori, Morley, Roland, Royer‐Joo, Stephanie, Pirzkall, Andrea, Salphati, Laurent, Ware, Joseph A., Morrissey, Kari M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624388/
https://www.ncbi.nlm.nih.gov/pubmed/30973970
http://dx.doi.org/10.1111/bcp.13961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624388/
https://www.ncbi.nlm.nih.gov/pubmed/30973970
http://dx.doi.org/10.1111/bcp.13961

Ejemplares similares